- Press Releases
- Notices
Press Releases To List
-
- Mar.14.2024Licensing
- Ono Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders
-
- Mar.12.2024R & D
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
-
- Mar.11.2024Sustainability
- Ono Selected as "2024 Health & Productivity Stock"
-
- Mar.11.2024Licensing
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
-
- Mar.06.2024Licensing
- Ono Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101
Notices To List
-
- Sep.26.2023Corporate
- Corporate Report 2023 has been released.
-
- Jun.23.2023Corporate
- Voting Results (Extraordinary Report) of the 75th Ordinary General Shareholders’ Meeting
-
- Jun.22.2023Corporate
- Notice to Resolutions Passed at The 75th Ordinary General shareholders’ Meeting
-
- May.25.2023Corporate
- Notice to Convene the 75th Ordinary General Shareholders' Meeting
-
- Sep.22.2022Corporate
- Announcement on posting of Corporate Report 2022
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.